Evidence map›Paper›PMID 24584347›Full record

ArticleHaematologica2014

MicroRNA-23a mediates post-transcriptional regulation of CXCL12 in bone marrow stromal cells.

Laleh S Arabanian, Fernando A Fierro, Friedrich Stölzel, Carolin Heder, David M Poitz, Ruth H Strasser, Manja Wobus, Martin Borhäuser, Ruben A Ferrer, Uwe Platzbecker and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 31 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Connexin's Connection in Breast Cancer Growth and Progression.International journal of cell biology · 2016
    Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Laleh S ArabanianDepartment of Medicine I, University Hospital Carl Gustav Carus, Dresden University of Technology, Germany Laleh.arabanian@gu.se.
Fernando A FierroInstitute for Regenerative Cures, University of California, Davis, CA, USA.
Friedrich StölzelDepartment of Medicine I, University Hospital Carl Gustav Carus, Dresden University of Technology, Germany.
Carolin HederDepartment of Medicine I, University Hospital Carl Gustav Carus, Dresden University of Technology, Germany.
David M PoitzMedical Clinic of Internal Medicine and Cardiology, Dresden University of Technology, Germany.
Ruth H StrasserMedical Clinic of Internal Medicine and Cardiology, Dresden University of Technology, Germany.
Manja WobusDepartment of Medicine I, University Hospital Carl Gustav Carus, Dresden University of Technology, Germany.
Martin BorhäuserDepartment of Medicine I, University Hospital Carl Gustav Carus, Dresden University of Technology, Germany.
Ruben A FerrerDepartment of Medicine I, University Hospital Carl Gustav Carus, Dresden University of Technology, Germany.
Uwe PlatzbeckerDepartment of Medicine I, University Hospital Carl Gustav Carus, Dresden University of Technology, Germany.
Matthias SchiekerExperimental Surgery and Regenerative Medicine, Department of Surgery, Ludwig-Maximilians-University, Munich, Germany.
Denitsa DochevaExperimental Surgery and Regenerative Medicine, Department of Surgery, Ludwig-Maximilians-University, Munich, Germany.
Gerhard EhningerDepartment of Medicine I, University Hospital Carl Gustav Carus, Dresden University of Technology, Germany.
Thomas IllmerDepartment of Medicine I, University Hospital Carl Gustav Carus, Dresden University of Technology, Germany.
University Hospital Carl Gustav Carus · DELudwig-Maximilians-Universität München · DETU Dresden · DECalifornia Institute for Regenerative Medicine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The chemokine CXCL12 regulates the interaction between hematopoietic stem and progenitor cells and bone marrow stromal cells. Although its relevance in the bone marrow niche is well recognized, the regulation of CXCL12 by microRNA is not completely understood. We transfected a library of 486 microRNA in the bone marrow stromal cell line SCP-1 and studied the expression of CXCL12. Twenty-seven microRNA were shown to downregulate expression of CXCL12. Eight microRNA (miR-23a, 130b, 135, 200b, 200c, 216, 222, and 602) interacted directly with the 3'UTR of CXCL12. Next, we determined that only miR-23a is predicted to bind to the 3'UTR and is strongly expressed in primary bone marrow stromal cells. Modulation of miR-23a changes the migratory potential of hematopoietic progenitor cells in co-culture experiments. We discovered that TGFB1 mediates its inhibitory effect on CXCL12 levels by upregulation of miR-23a. This process was partly reversed by miR-23a molecules. Finally, we determined an inverse expression of CXCL12 and miR-23a in stromal cells from patients with myelodys-plastic syndrome indicating that the interaction has a pathophysiological role. Here, we show for the first time that CXCL12-targeting miR23a regulates the functional properties of the hematopoietic niche.

Indexed as

Gene Expression RegulationRNA InterferenceRNA Processing, Post-TranscriptionalCell LineChemokine CXCL12Gene ExpressionHumansMesenchymal Stem CellsMicroRNAsMyelodysplastic SyndromesReproducibility of ResultsRNA, MessengerTransfectionChemokine CXCL12MicroRNAsMIRN23a microRNA, humanRNA, Messenger

Identifiers

PMID24584347
PMCPMC4040896
OpenAlexW2094248701

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.